参考文献

1.NCCN Clinical Practice Guidelines in Oncology(NCCN Guidelines): Kidney Cancer Version 2.2019 — September 17, 2018.

2.American Joint Committee on Cancer(AJCC)Cancer Staging System(8th ed., 2017).

3.Howlader N, Noone A, Krapcho M, et al.SEER Cancer Statistics Review, 1975—2014, based on November 2016 SEER data submission, posted to the SEER web site, April 2017: National Cancer Institute.Bethesda, MD, 2017.

4.Haas NB, Manola J, Dutcher JP, et al.Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial.JAMA Oncol 2017, 3: 1249-1252.

5.Motzer RJ, Haas NB, Donskov F, et al.Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.J Clin Oncol 2017, 35: 3916-3923.(https://www.daowen.com)

6.Motzer RJ, Ravaud A, Patard JJ, et al.Adjuvant Sunitinib for Highrisk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.Eur Urol 2018, 73: 62-68.

7.Motzer RJ, Tannir NM, McDermott DF, et al.Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma.N Engl J Med 2018, 378: 1277-1290.

8.Ravaud A, Motzer RJ, Pandha HS, et al.Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.N Engl J Med 2016, 375: 2246-2254.

9.Sheng X, Chi Z, Cui C, et al.Efficacy and safety of sorafenib versus sunitinib as first-line treatment in patients with metastatic renal cell carcinoma: largest single-center retrospective analysis.Oncotarget 2016, 7: 27044-27054.

10.Armstrong AJ, Halabi S, Eisen T, et al.Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma(ASPEN): a multicentre, open-label, randomised phase 2 trial.Lancet Oncol 2016, 17: 378-388.